

CURRICULUM VITAE

Bruce William Stanley ROBINSON

1. PERSONAL DETAILS

PLACE OF BIRTH: Perth, Western Australia
NATIONALITY: Australian
ADDRESS:
Work: School of Medicine
University of Western Australia, M503
35 Stirling Hwy CRAWLEY WA 6009 AUSTRALIA
Tel: (08) 6151 0915 Fax: (08) 6151 1027 (national)
Tel: 61 8 6151 0915 Fax: 61 8 6151 1027 (international)

2. EDUCATION; AWARDS; SCHOLARSHIPS AND FELLOWSHIPS

2.1 Educational Qualifications

Matriculation	1967	Perth, Western Australia (5 distinctions)
MBBS	1974	University of Western Australia
DTM&H	1976	University of Liverpool (School of Tropical Medicine)
MRCP	1977	Royal College of Physicians (United Kingdom)
FRACP	1981	Royal Australasian College of Physicians
FCCP	1987	American College of Chest Physicians
MD	1987	University of Western Australia
FRCP	1995	Royal College of Physicians (UK)

2.2 Awards

Irving Selikoff Lifetime Achievement Award of the International Asbestos Awareness Organisation, 2017.

Royal Australasian College of Physicians (RACP) 75th Anniversary Award, 2014.

WA Australian of the Year, 2014.

Western Australian of the Year 2013.

Winner, Business and Professions Category, Western Australian of the Year Awards, 2013.

Member of the Order of Australia (General Division), Australia Day Honours List, 2013, for significant service to medicine in the area of research into asbestos-related cancers, and to the community, particularly through support to fathers.

The Ernst & Young Entrepreneur of the Year Award, 2011, for the International Skills and Training Institute in Health (ISTIH).

The Australian Medical Association Award, 2010, for outstanding contributions to a variety of fields of medicine.

The Research Medal of the Thoracic Society of Australia and New Zealand, March 2007. This Award is made in recognition of outstanding contributions to scientific research.

The Premier's Science Award, Western Australia, 2004. Presented to the individual chosen by the Premier's Science Council for their achievements and leadership in science.

The Wagner Medal, 2004. An award made every second year by the committee of the International Mesothelioma Interest Group and presented at their International Conference to the individual who is judged to have made the leading contribution to mesothelioma research over a number of years.

The Gordon Ada Oration, Australasian Society for Immunology, Tumour Immunology Workshop, December 2004.

The Teacher of the Year award, 1999, The University of Western Australia, School of Medicine (selected by the medical student body).

The Excellence in Teaching award, 1997, The University of Western Australia, Faculty of Medicine & Dentistry.

The Eric G Saint Award, 1996, for contributions to research into asbestos-related diseases.

The Teacher of the Year award, 1990, The University of Western Australia, School of Medicine (selected by the medical student body).

The Young Investigator Award of the Thoracic Society of Australia, 1986, for 'The most outstanding scientific work by an investigator under 36 years of age'.

Scholarships/Fellowships awarded:

NH & MRC Special Training Fellowship 1986

NH & MRC Applied Health Sciences Fellowship 1983-1985
Royal Australasian College of Physicians Overseas Fellowship 1982
Saw Medical Research Fellowship 1982
Commonwealth University Scholarship 1968-1973
Commonwealth Secondary Scholarship 1964-1967

3. EXPERIENCE

1995-present *Professor of Medicine*
Department of Medicine, The University of Western Australia
Sir Charles Gairdner Hospital, Perth, Western Australia.

1984-present *Consultant Physician*
Department of Respiratory Medicine (plus General Medicine 1988-1997)
Sir Charles Gairdner Hospital, Perth, Western Australia.

2007-2018 *Director, National Research Centre for Asbestos Related Diseases (NCARD)*
The University of Western Australia, Perth Western, Australia

1997-1999 Director, Institute for Advanced Medical Research
The University of Western Australia

1996-2001 Director, Office of Research Development
Sir Charles Gairdner Hospital, Perth, Western Australia.

1992 Sabbatical Leave c/-Professor J Lamb
Department of Immunology, St Mary's Hospital Medical School
London, United Kingdom.

1991-1994 Associate Professor of Medicine
Department of Medicine, The University of Western Australia
Sir Charles Gairdner Hospital, Perth, Western Australia

1988-1990 Senior Lecturer in Medicine
Department of Medicine, The University of Western Australia

1984-1987 Research Fellow
Department of Medicine, The University of Western Australia

1982-1984 Guest Worker, Pulmonary Branch and Physician-in-Charge (on rotation)
Clinical Service, Pulmonary Function Testing, Pulmonary Branch
Clinical Center, National Institutes of Health
Bethesda, Maryland, United States of America

1979-81 Sir Charles Gairdner Hospital, Perth, Western Australia

1979 Medical Registrar/General Medicine, Endocrinology, Renal Medicine

1980 Registrar, Respiratory Medicine

1981 Senior Registrar, Respiratory Medicine and Postgraduate Medical Education.

1977-1978 Senior Registrar
General Medicine, Geriatrics, Respiratory
Guy's Hospital, London, United Kingdom.

1976-1977 Medical Registrar/Medical Assistant
Chest Medicine, General Medicine
Southend Hospital, Southend, Essex, United Kingdom.
Full time course in Tropical Medicine and Hygiene
September - December, 1976. University of Liverpool.

1974-1975 Resident Medical Officer
Royal Perth Hospital, Western Australia.
General Medicine, Cardiology, Rheumatology, Neurology, Anaesthetics, Neurosurgery,
Casualty, General Surgery
term in Papua New Guinea.

4. Published Books

1. Kradin RL, Robinson BWS. Immunopathology of Lung Disease. Butterworth-Heinemann, Boston. 1996. [ISBN: 0-7506-9282-0].
2. Robinson BWS, Chahinian P. Mesothelioma. Martin Dunitz. 2002. [ISBN:9-05823-180-1].
3. Robinson BWS. Fathering from the Fast Lane. Finch Publishing, Sydney. 2002. [ISBN:1-876451-21-1].
4. Robinson, Bruce. The Blue Book of Tips for Fathers and Father Figures. 2007. MACSIS Publishing, Perth. [ISBN 978-0-9805134-1-7].
5. Robinson, Bruce. Daughters and their Dads. 2008. MACSIS Publishing, Perth. [ISBN 978-0-9805134-0-0]

6. Robinson, Bruce. *Fathering in the UK*. MACSIS Publishing, Perth 2013. E-book
7. Robinson, Bruce. *Dads Down Under*. MACSIS Publishing, Perth 2013. E-book
8. Robinson, Bruce. *FatheringUSA*. MACSIS Publishing, Perth 2013. E-book

5. Published Papers last 10 years

157. Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. *Clin Chem Lab Med*. 2010 Jun;48(6):869-74.
158. McDonnell AM, Prosser AC, van Bruggen I, Robinson BWS, Currie AJ. CD8 α + DCs are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. *European Journal of Immunology* 2010; 40 (6): 1617-1627.
159. Kurts C, Robinson BWS, Knolle PA. Cross-priming in health and disease. *Nature Reviews Immunology* 2010 10 (6): 403-414.
160. Creaney J, Musk AW, Robinson BW. Sensitivity of urinary mesothelin in patients with malignant mesothelioma. *J Thorac Oncol*. 2010 Sep;5(9):1461-6.
161. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. *Cancer Epidemiol Biomarkers Prev*. 2010 Sep;19(9):2238-46.
162. Steer HJ, Lake RA, Nowak AK, Robinson BW. Harnessing the immune response to treat cancer. *Oncogene*. 2010 29, 6301-6313.
163. McDonnell AM, Robinson BW, Currie AJ. Tumour antigen cross-presentation and the dendritic cell: where it all begins? *Clin Dev Immunol*. 2010;2010:539519. (Review).
164. Creaney, J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumour volume, clinical stage and changes in tumour burden. *Clin Cancer Res*. 2011 Mar 1; 17(5): 1181-9.
165. Robinson B, Alatas MF, Robertson A, Steer H. Natural Disasters and the Lung Respirioly. 2011 Apr 16(3): 386-395.
166. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function - analysis of relationship and implications for mesothelioma screening. *Lung Cancer*. 2011 Sep; 73(3): 320-4.
167. Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma- Which is best? *Lung Cancer*. 2011 Oct; 74(1): 55-60.
168. Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BW, Rusch VW, Sugarbaker DJ, van Zandwijk N. The MARS feasibility trial: conclusions not supported by data. *Lancet Oncology* 2011 Nov; 12 (12): 1093-4.
169. Creaney J, Dick Ian M, Yeoman D, Wong S, Robinson BWS. Auto-antibodies to β -F1-ATPase and Vimentin in Malignant Mesothelioma. *PlosOne* 2011 Oct 6 (10) e26515..
170. Hollevoet K, Reitsma JB, van Meerbeeck JP, Baas P, Creaney J, Cristaudo A, Di Serio F, Grigoriu D, Muley T, Nackaerts K, Pass HI, Rai AJ, Robinson BW, Rodriguez Portal JA, Scherpereel A, Schneider J, Tomasetti M. Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. *Journal of Clinical Oncology*. 2012 30 (13): 1541-1549. (Review).
171. Park EK, Yates DH, Creaney J, Thomas, PS, Robinson BW and Johnson AR. Association of Biomarker Levels with Severity of Asbestos-Related Diseases. *Safety and Health at Work* 2012 3: 17-21.
172. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JB, Armstrong NJ, Valley MP, Musk AW, Robinson BWS, McCaughan BC, Klebe S, Mutsaers SE, van Zanwijk N, Reid G. Increased Circulating miR-625-3p A Potential Biomarker for Patients with Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*. 2012. Jul; 7 (7): 1184-91.
173. Khong A, Nelson D, Nowak A, Lake R and Robinson BWS. The use of agonistic anti-CD therapy in treatments for cancer. *International Reviews of Immunology*. 2012.Aug 31(4): 246-66.
174. McDonnell AM, Currie AJ, Brown M, Kania K, Wylie B, Cleaver A, Lake R and Robinson BWS. Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. *Oncoimmunology* 2012:1:7, pp 1-7 Oct.
175. Jackaman C, Lansley S, Allan JE, Robinson BW, Nelson DJ. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. *Int Immunol*. 2012 Jun;24(6):357-68.
176. Brown MD, van Der Most R, Vivian JB, Lake RA, Larma I, Robinson BWS, and Currie AJ. Loss of Antigen Cross-Presentation After Complete Tumour Resection is Associated with the Generation of Protective Tumour-Specific CD8+ T Cell Immunity. *Oncoimmunology* 2012 1 Oct; 1(7): 1084-1094.
177. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. *Clin Dev Immunol*. 2012;2012:656340. (Review).
178. Eastwood PR, Naughton MT, Calverley P, Zeng G, Beasley R, Robinson B and Lee YCG. How to write research papers and grants: 2011 Asian Pacific Society for Respirioly Annual Scientific Meeting Postgraduate Session. *Respirioly* 2012 17, 792-801 (Invited Review).

179. Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J, A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. *Pathology* 2013 Jan 45 (1) 44-8.
180. Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? *Lung Cancer* 2013 Apr; 80(1): 39-44.
181. Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, Cadby G, Di Gaetano C, Rosa F, Russo A, Hirvonen A, Casalone E, Tunesi S, Padoan M, Giordano M, Aspesi A, Casadio C, Ardisson F, Ruffini E, Betta PG, Libener R, Guaschino R, Piccolini E, Neri M, Musk AW, de Klerk NH, Hui J, Beilby J, James AL, Creaney J, Robinson BW, Mukherjee S, Palmer LJ, Mirabelli D, Ugolini D, Bonassi S, Magnani C, Dianzani I. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. *PLoS One*. 2013 Apr 23;8(4):e61253. doi: 10.1371/journal.pone.0061253. Print 2013. Erratum in: *PLoS One*. 2015;10(6):e0130109. PubMed PMID: 23626673; PubMed Central PMCID: PMC3634031.
182. Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW, Lake RA. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. *Plos One*. 2013 Apr 23;8(4):e61895.
183. Cadby G, Mukherjee S, Musk AW, Reid A, Garlepp M, Dick I, Robinson C, Hui J, Fiorito G, Guarrera S, Beilby J, Melton PE, Moses EK, Ugolini D, Mirabelli D, Bonassi S, Magnani C, Dianzani I, Matullo G, Robinson BW, Creaney J, Palmer LJ. A genome-wide association study for malignant mesothelioma risk. *Lung Cancer*. 2013 Oct 82 (1): 1-8.
184. Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates S, Robinson BWS. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor as biomarkers for mesothelioma in pleural effusions and serum. *Disease Markers*. 2013 Aug 35 (2) pp 119-27.
185. Khong A, Brown MD, Vivian JB, Robinson BWS, Currie AJ. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. *Journal of Immunotherapy*, 2013 Sep 36 (7) 365-72.
186. Creaney J, Dick IM, Segal A, Musk AW and Robinson BWS. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. *Lung Cancer*, 2013 Dec 82 (3):491-498.
187. Cleaver AL, Bhamidipaty K, Wylie B, Connor T, Robinson C, Robinson BW, Mutsaers SE, Lake RA. Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance. *Carcinogenesis*, 2014 Feb 35 (2): 407-14.
188. Nelson D, Fisher S and Robinson BWS. The “Trojan Horse” approach to tumor immunotherapy: targeting the tumor microenvironment. *Journal of Immunology Research*, 2014 May e789069. (Review).
189. Creaney J, Dick IM, Meniawy TM, Leong S, Leon JS, Demelker Y, Segal A, Musk AW, Lee, YCG, Skates SJ, Nowak AK and Robinson BWS. Comparison of fibulin-3 and mesothelioma as markers in malignant mesothelioma. *Thorax*, 2014 Oct 69 (10): 895-902.
190. Robinson C, Alfonso H, Woo S, Olsen N, Musk AW, Robinson BWS, Nowak AK, Lake RA. Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans. *PLOS One* 2014 Aug 9 (8) e103125.
191. Fisher SA, Cleaver A, Lakiani DD, Khong A, Connor T, Wylie B, Lesterhuis WJ, Robinson BW, Lake RA. Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. *Journal of Translational Medicine*. 2014, Sep 12: 245, pp 1-9.
192. Anyaegbu CC, Lake RA, Heel K, Robinson BW, Fisher SA. Chemotherapy enhances cross-presentation of nuclear tumour antigens. *PLOS ONE* 2014, Sep, 9 (9) e107894.
193. Robinson C, Alfonso H, Woo S, Olsen N, Musk AW, Robinson BWS, Nowak AK, Lake RA. Effect of NSAIDs and COX-2 inhibitors on the incident and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort. *Lung Cancer*. 2014 1 October 86 (1):29-34.
194. Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. *Disease Markers* 2014 Nov e413946
195. Khong A, Cleaver AL, Alatas MF, Wylie BC, Connor T, Fisher SA, Broomfield S, Lesterhuis WJ, Currie AJ, Lake RA, Robinson BW. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. *BMC cancer*. 2014 Dec, 14(1):969.
196. McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ and Robinson BWS. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. *European Journal of Immunology*. 2015 Jan;45(1):49-59.
197. McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ and Robinson BWS. Restoration of defective cross-presentation in tumours by gemcitabine. *Oncolmmunology*. 2015 4 (5).
198. Creaney J, Dick IM, Robinson BWS. Discovery of new biomarkers for malignant mesothelioma. *Current Pulmonology Reports*. 2015, 4 (1) pp 15-21. (Review).
199. Creaney J, Ma S, Sneddon S, Tourigny M, Dick IM, Leon J, Khong A, Fisher SA, Lake RA, Lesterhuis WJ, Nowak AK, Leary S, Watson M, Robinson BWS. Strong spontaneous tumour neo-antigen responses to tumors induced by a natural human carcinogen. *Oncolmmunology*. 2015 May 4:7 e1011492-1.

200. Leong SL, Zainudin R, Kazan-Allen L, Robinson BW. Asbestos In Asia. *Respirology*. 2015 May 20 (4): 548-555.
201. Leong SL, Lee YCG, Robinson BWS, Creaney JC. Role of mesothelin management in patients with cytology-negative pleural effusion undergoing medical thoracoscopy. *Pleura*, 2015 April 21, pp 1-7.
202. Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJN, Moses EK, Melton PE, de Klerk N, Musk AW, Robinson BWS, Creaney J. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. *Gene* 2015 25 May 563 (1): 103-105.
203. Lesterhuis WJ, Rinaldi C, Jones A, Rozali EN, Dick IM, Khong A, Boon L, Robinson BW, Nowak AK, Bosco A, Lake RA. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. *Scientific Reports* 2015 5, art. No. 12298.
204. Creaney J, Dick IM, Robinson BW. Comparison of slin-3 in pleural fluid and serum as markers in malignant mesothelioma. (Review). 2015. *Current Opinion in Pulmonary Medicine*. July 21 (4), 352-356.
205. Steer HJ, Robinson BWS. Axillary crackles are more prevalent than basal crackle in asbestos exposed workers with asbestosis. *Jacobs Journal of Pulmonology* 2015 1 (1) 04.
206. Robinson C, Dick IM, Wise MJ, Holloway A, Diyagama D, Robinson BWS, Creaney J, Lake RA. Consistent gene expression profiles in MexTag transgenic mouse and wild type mouse asbestos-induced mesothelioma. *BMC Cancer*. 2015 Dec 18, 15 (1) article no. 983.
207. Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, McCoy MJ, Robinson BW, Lake RA. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. 2016. *Annals of Oncology* Dec 26 (12) 2483-90.
208. Morre, DJ, Hostetler B; Taggart DJ; Morre DM, Musk AW, Robinson BWS; Creaney J. ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma four to ten years in advance of clinical symptoms. *Clinical Proteomics*. 2016. Feb 22, 13 (3) , art. doi: 10.1186/s12014-016-9105-1. eCollection 2016
209. Morre, DJ, Hostetler B; Taggart DJ; Morre DM, Musk AW, Robinson BWS; Creaney J. Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma four to ten years in advance of clinical symptoms. *Clinical Proteomics*. 2016. Jan 13 (1) , art. no. 9103.
210. Creaney J, Dick IM, Musk AW, Olsen NJ, Robinson BWS. Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. 2016. *Biomarkers*. 2016 Sep; 21(6):551-61.
211. Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. *Respirology*. 2016. Apr 21. (Invited Review).
212. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. *European Respiratory Review*. 2016. 25 (140) DOI 10.1183/16000617.0019-2016 1 June pp 189-98.
213. Greening DW, Hong J, Chen M, Robinson BWS, Dick IM, Creaney J, Simpson RJ. Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. *Scientific Reports* 2016 Sep 8;6:32643. doi: 10.1038/srep32643.
214. Fisher SA, Aston WJ, Chee J, Khong A, Cleaver AL, Solin JN, Ma S, Lesterhuis WJ, Dick IM, Holt RA, Creaney J, Boon L, Robinson BW, Lake RA. Transient Treg depletion enhances therapeutic anti-cancer vaccine. *Immunity Inflammation and Disease* 2016 Nov 21; 5 (1):16-28. doi: 10.1002/iid3.136. eCollection 2017 Mar.
215. Creaney J, Dick IM, Leon JS, Robinson BWS. A proteomic analysis of the malignant mesothelioma secretome using iTRAQ. *Cancer Genomics & Proteomics*. 2017 14 (2) 103-17.
216. Chee J, Robinson BWS, Holt RA, Creaney J. Immunotherapy for lung malignancies from gene sequencing to novel therapies. 2017 *Chest*. 151 (4), 891-7.
217. Sneddon S, Patch A-M, Dick IM, Kazakoff S, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. *BMC Cancer* 2017 17: 396 DOI 10.1186/s12885-017-3382-6
218. Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, Taeger D, Lehnert M, Kollmeier J, Bauer T, Musk AW, Robinson BWS, Brüning T, Creaney J. Calretinin as a blood-based biomarker for mesothelioma. *BMC Cancer* 2017 17: 386.
219. McDonnell AM, Cook A, Robinson BWS, Lake RA, Nowak AK. Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. *BMC Cancer* 2017 17: 417.
220. Creaney J and Robinson BWS. Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening and treatment. *Chest* 2017 July 152 (1) 143-149.
221. Aston WJ, Hope DE, Nowak AK, Robinson BWS, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. *BMC Cancer* 2017 17 (1) 16 October art. 684.

222. Patch AM, Nones K, Kazakoff SH, Newell F, Wood S, Leonard C, Holmes O, Xu Q, Addala V, Creaney J, Robinson BW, Fu S, Geng C, Li T, Zhang W, Liang X, Rao J, Wang J, Tian M, Zhao Y, Teng F, Gou H, Yang B, Jiang H, Mu F, Pearson JV, Waddell N. Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing. *PLoS One*. 2018 Jan 10;13(1):e0190264
223. Sneddon S, Dick IM, Lee YCG, Musk AW, Patch A-M, Pearson J, Waddell N, Allcock RJN, Holt RA, Robinson BW, Creaney J. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. *Lung Cancer* 2018 Vol 119 May pp 64-70.
224. Marini KD, Croucher DR, McCloy RA, Gonzalez-Rajal A, Hastings JF, Chin V, Kostyrko K, Jayasekara S, Alamegeer M, Boolell V, Vaghiani V, Szczepny A, Han JZR, Waugh T, Lee HC, Oakes SR, Kumar B, Harrison CA, Hedger MP, Lorensuhewa N, Kita B, Barrow R, Robinson BW, de Kretser DM, Wu J, Ganju V, Sweet-Cordero EA, Burgess A, Martelotto LG, Rossello FJ, Cain JE, Watkins DN. Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. *Science Translational Medicine* 2018 25 July, Vol 10 Issue 451 Article eaat3504.
225. Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Joost Lesterhuis W, Dick IM, Nowak AK, Robinson BW, Lake RA, Fisher SA. Combination immune checkpoint blockade as an effective therapy for mesothelioma. *Oncoimmunology*. 2018 Jul 30;7(10):e1494111.
226. Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. *J Thorac Oncol*. 2018 Sep;13(9):1269-128
227. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. *J Thorac Oncol*. 2018 Nov;13(11):1655-166
228. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Grait K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravagnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. *Cancer Discovery*. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15. PubMed PMID: 30322867; PubMed Central PMCID: PMC6310008.
229. Chee J, Watson MW, Chopra A, Nguyen B, Cook AM, Creaney J, Lesterhuis WJ, Robinson BW, Lee YCG, Nowak AK, Lake RA, McDonnell AM. BMC Research Notes 2018 Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors.11: 864 doi: 10.1186/s13104-018-3953-x.
230. Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE. Inhibition of collagen production delays malignant mesothelioma tumour growth in a murine model. *Biochemical and Biophysical Research Communications* 2019 510: 2, 5 March pp. 198-204.
231. Ye L, Ma S, Robinson BW, Creaney J. Immunotherapy strategies for mesothelioma - the role of tumour specific neoantigens in a new era of precision medicine. *Expert Review of Respiratory Medicine* 2019 13:2 181-192.
232. Neeve SC, Robinson BW, Fear VS. The role and therapeutic implications of T cells in cancer of the lung. *Clinical & Translational Immunology*. 2019;8(8):e1076.
233. Fear VS, Forbes CA, Chee J, Ma S, Neeve S, Celliers L, Fisher SA, Dick I, Creaney J, Robinson BWS. Neo-antigen specific T cell responses indicate the presence of metastases before imaging. *Sci Rep*. 2019 Oct 10;9(1):14640. doi: 10.1038/s41598-019-51317-3. PubMed PMID: 31601975.
234. Sneddon S, Rive CN, Ma S, Dick IM, Allcock RJN, Brown SD, Holt RA, Watson M, Leary S, Lee GYC, Robinson BWS. Creaney J. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. *Oncolmmunology* 2019, DOI: 10.1080/2162402X.2019.1684713
235. Cerciello F, Choi M, Sinicropi-Yao SL, et al. Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma [published online ahead of print, 2020 Jul 30]. *Cancer Epidemiol Biomarkers Prev*. 2020;cebp.0543.2020. doi:10.1158/1055-9965.EPI-20-0543
236. Ma S, Chee J, Fear VS, Forbes CA, Dick IM, Robinson BWS, Creaney J. Pre-treatment tumour neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. *Oncolmmunology* 2019

237. Jia Q, Chiu L, Wu S, et al. Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer. *Adv Sci (Weinh)*. 2020;7(9):1903410. Published 2020 Mar 26. doi:10.1002/advs.201903410
238. Fear VS, Forbes CA, Neeve SA, Fisher SA, Chee J, Waithman J, Ma SK, Lake R, Nowak AK, Creaney J, Brown MD, Saunders C, Robinson BWS. Correction to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. *Cancer Immunol Immunother*. 2021 Jun 5. doi: 10.1007/s00262-021-02970-z. Epub ahead of print. Erratum for: *Cancer Immunol Immunother*. 2021 Apr 9;: PMID:34089374
239. Cook AM, McDonnell A, Millward MJ, Creaney J, Hasani A, McMullen M, Meniawy T, Robinson BWS, Lake RA, Nowak AK. A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. *Expert Rev Anticancer Ther*. 2021 May;21(5):465-474. doi: 10.1080/14737140.2021.1882308. Epub 2021 Feb 9. PMID: 33509005.